The sum of these experimental evidences leads us to postulate a new role for G6PT in cancer cell signalling, and suggests that efficient inhibition of the G6PT functions will impact on the invasive and metastatic phenotype of circulating cancer cells whether they derive from solid tumors or from malignant clonal disorder of hematopoietic stem cells such as CML. Here, G6PC1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.